Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics (Nasdaq: LXEO), a clinical stage genetic medicine company, has announced its participation in several upcoming investor conferences. The company, which focuses on developing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, will be presenting at four major healthcare and investment events in September and October 2024:
- H.C. Wainwright 26th Annual Global Investment Conference on September 9
- Baird 2024 Global Healthcare Conference on September 10
- Cantor 2024 Global Healthcare Conference on September 18
- Chardan's 8th Annual Genetic Medicines Conference on October 1
All presentations will be webcast live and available for replay on the company's website under the Investors section.
Lexeo Therapeutics (Nasdaq: LXEO), un'azienda di medicina genetica in fase clinica, ha annunciato la sua partecipazione a diverse conferenze per investitori nei prossimi mesi. L'azienda, che si concentra sullo sviluppo di trattamenti per malattie cardiovascolari geneticamente definite e la malattia di Alzheimer associata ad APOE4, presenterà in quattro eventi principali dedicati alla salute e agli investimenti a settembre e ottobre 2024:
- 26a Conferenza Globale di Investimento Annuale H.C. Wainwright il 9 settembre
- Conferenza Globale sulla Sanità 2024 di Baird il 10 settembre
- Conferenza Globale sulla Sanità 2024 di Cantor il 18 settembre
- 8a Conferenza Annuale sui Medicinali Genetici di Chardan il 1 ottobre
Tutte le presentazioni saranno trasmesse in diretta e disponibili per essere riviste sul sito web dell'azienda nella sezione Investitori.
Lexeo Therapeutics (Nasdaq: LXEO), una empresa de medicina genética en etapa clínica, ha anunciado su participación en varias conferencias de inversores que se aproximan. La empresa, que se centra en desarrollar tratamientos para enfermedades cardiovasculares definidas genéticamente y la enfermedad de Alzheimer asociada a APOE4, estará presentando en cuatro grandes eventos de salud e inversiones en septiembre y octubre de 2024:
- 26ª Conferencia Anual Global de Inversión H.C. Wainwright el 9 de septiembre
- Conferencia Global de Salud 2024 de Baird el 10 de septiembre
- Conferencia Global de Salud 2024 de Cantor el 18 de septiembre
- 8ª Conferencia Anual de Medicamentos Genéticos de Chardan el 1 de octubre
Todas las presentaciones serán transmitidas en vivo y estarán disponibles para su reproducción en el sitio web de la compañía en la sección de Inversores.
Lexeo Therapeutics (Nasdaq: LXEO)는 임상 단계의 유전자 치료 회사로, 다가오는 여러 투자자 회의에 참여한다고 발표했습니다. 이 회사는 유전적으로 정의된 심혈관 질환과 APOE4 관련 알츠하이머병 치료제를 개발하는 데 중점을 두고 있으며, 2024년 9월과 10월에 진행되는 네 개의 주요 건강 및 투자 행사에서 발표할 예정입니다:
- 9월 9일 H.C. Wainwright 제26회 연례 글로벌 투자 회의
- 9월 10일 Baird 2024 글로벌 헬스케어 회의
- 9월 18일 Cantor 2024 글로벌 헬스케어 회의
- 10월 1일 Chardan 제8회 연례 유전자 의약품 회의
모든 발표는 실시간 방송되며, 회사 웹사이트의 투자자 섹션에서 다시 볼 수 있습니다.
Lexeo Therapeutics (Nasdaq: LXEO), une entreprise de médecine génétique en phase clinique, a annoncé sa participation à plusieurs conférences d'investisseurs à venir. L'entreprise, qui se concentre sur le développement de traitements pour des maladies cardiovasculaires définies génétiquement et la maladie d'Alzheimer associée à APOE4, présentera lors de quatre événements majeurs de santé et d'investissement en septembre et octobre 2024 :
- 26ème Conférence Annuelle Globale d'Investissement H.C. Wainwright le 9 septembre
- Conférence Globale de Santé 2024 de Baird le 10 septembre
- Conférence Globale de Santé 2024 de Cantor le 18 septembre
- 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan le 1er octobre
Toutes les présentations seront diffusées en direct et disponibles en rediffusion sur le site Web de l'entreprise dans la section Investisseurs.
Lexeo Therapeutics (Nasdaq: LXEO), ein Unternehmen für genetische Medizin in der klinischen Phase, hat seine Teilnahme an mehreren bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für genetisch definierte Herz-Kreislauf-Erkrankungen und APOE4-assoziierte Alzheimer-Krankheit konzentriert, wird bei vier großen Gesundheits- und Investitionsveranstaltungen im September und Oktober 2024 präsentieren:
- 26. Jährliche Globale Investorenkonferenz von H.C. Wainwright am 9. September
- Baird 2024 Globale Gesundheitskonferenz am 10. September
- Cantor 2024 Globale Gesundheitskonferenz am 18. September
- 8. Jährliche Konferenz für Genetische Medikamente von Chardan am 1. Oktober
Alle Präsentationen werden live übertragen und auf der Website des Unternehmens im Investorenbereich für eine Wiederholung verfügbar sein.
- None.
- None.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:
| H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET | |
| Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 1:25 PM ET | |
| Cantor 2024 Global Healthcare Conference on Wednesday, September 18, 2024 at 11:30 AM ET | |
| Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:30 PM ET | |
The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
Media Response:
media@lexeotx.com
Investor Response:
Stephen Jasper
(858) 525-2047
stephen@gilmartinir.com
FAQ
What investor conferences will Lexeo Therapeutics (LXEO) attend in September and October 2024?
How can investors access Lexeo Therapeutics' (LXEO) conference presentations?
What are the main focus areas of Lexeo Therapeutics (LXEO)?
When is Lexeo Therapeutics (LXEO) presenting at the Chardan's Genetic Medicines Conference in 2024?
